Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Total Current Liabilities (2018 - 2025)

Dna X's Total Current Liabilities history spans 8 years, with the latest figure at $48.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $48.0 million for Q4 2025, up 9.8% from a year ago — trailing twelve months through Dec 2025 was $48.0 million (up 9.8% YoY), and the annual figure for FY2025 was $48.0 million, up 9.8%.
  • Total Current Liabilities for Q4 2025 was $48.0 million at Dna X, up from $38.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $48.0 million in Q4 2025 to a low of $19.9 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $30.2 million (2023), against an average of $30.4 million.
  • The sharpest move saw Total Current Liabilities fell 29.33% in 2024, then soared 65.33% in 2025.
  • Year by year, Total Current Liabilities stood at $21.0 million in 2021, then skyrocketed by 52.79% to $32.1 million in 2022, then increased by 0.27% to $32.1 million in 2023, then surged by 36.06% to $43.7 million in 2024, then rose by 9.8% to $48.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $48.0 million, $38.9 million, and $35.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.